X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used to support the Sarcopenia project which focuses on the development of muscle progenitor cells which will be loaded with Genflow's proprietary SIRT6 for sarcopenia.
Lead Product(s): Muscle Progenitor Cells
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Government of Wallonia
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Funding May 30, 2024
Details:
This collaborative effort aims to expand and diversify Genflow's research pipeline for conditions such as Sarcopenia, the progressive loss of muscle mass and function associated with ageing.
Lead Product(s): Undisclosed
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Revatis SA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2024
Details:
This collaboration aims to develop a novel mRNA delivery system using exosomes to encapsulate and transport Genflow’s proprietary centenarian SIRT6 gene to revolutionize therapeutic interventions including GF-3001 for Werner Syndrome.
Lead Product(s): GF-3001
Therapeutic Area: Genetic Disease Product Name: GF-3001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: EXO Biologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
